3Flaherty SA, Pain measurement tools for clinical practice and research[J]. AANA J, 1996,64(2) :133-140.
4Yaman C, Jesacher K, Polz W. Accuracy of three-dimensional transvaginal ultrasound in uterus volume measurements: comparison with two-dimensional ultrasound[J]. Ultrasound Med Biol, 2003,29(12) :1681-1684.
5Fraser IS, Critchley HOD, Munro MG, et al. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of uterine bleeding [J]. FertilSteril, 2007,87(3) :466-476.
6Cho SH, Nam A, Kim HY, et al. Clinical effects of the levonorgestrel releasing intrauterine device in patients with adenomyosis[J]. Am J Obstet Gynecol, 2008, 198 (4): 373e1-e7.
7Sheng J, Zhang WY, Zhang JP, et al. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis[J]. Contraception, 2009,79(3):189-193.
8Rizkalla HF, Higgins M, Kelehan P, et al. Pathological findings associated with the presence of a Mirena intrauterine system at hysterectomy[J]. Int J Gynecol Pathol, 2008,27 (1) :74-78.
9Ko HS, Singh K. The effect of levonorgestrel-releasing intrauterine system use on menstrual blood loss and the hemostatic, fibrinolytic/inhibitor systems in women with menorrhagia [J]. J Thromb Haemost, 2007,5(1) :133-138.
10Escudero F, Gonzales G, Delgadillo L, et al. Factors associated with discontinuation rates of the Copper T380A IUD in a Peruvian public hospital[J]. Adv Contracept, 1999, 15 (4): 303-311.
